Evan C. Chen
YOU?
Author Swipe
View article: Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization
Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization Open
Introduction Recent evidence showing benefit of blinatumomab (blina), a CD19xCD3, in upfront treatment of B-cell acute lymphocytic leukemia (B-ALL) broadly expands its use (Litzow et al., NEJM 2024). Due to risks of cytokine release syndro…
View article: Real-world treatment patterns and clinical outcomes in patients with essential thrombocythemia treated with cytoreductive therapy: A retrospective analysis of electronic health records data
Real-world treatment patterns and clinical outcomes in patients with essential thrombocythemia treated with cytoreductive therapy: A retrospective analysis of electronic health records data Open
Background: Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, risk of thrombosis and bleeding, and progression to post-ET myelofibrosis (MF) or blast-phase disease. Cyt…
View article: No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse Open
Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) portends a dismal prognosis. One approach for reinvigorating a graft-vs-leukemia response is consolidation with donor lymphocyte infusions…
View article: Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia Open
Predictive biomarkers can potentially meet the need for improved drug assignment in acute myeloid leukemia (AML). Fewer than half of AML patients have actionable mutations: consequently, targeted therapy achieves remission in only a fracti…
View article: CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia Open
CAR-T treatment for B-cell acute lymphoblastic leukemia (ALL) induces high initial response rates, but most patients relapse. Low disease burden (often defined as < 5% blasts in the bone marrow) is associated with better outcomes. CAR-H…
View article: Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy Open
Tisagenlecleucel (tisa-cel) and brexucabtagene autoleucel (brexu-cel) are approved CD19 chimeric antigen receptor T-cell therapy (CAR T) products for young adults (YA) with relapsed/refractory B-cell acute lymphoblastic leukemia. A distinc…
View article: NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival Open
Introduction: Brexucabtagene autoleucel (brexu cel) is a CD19-targeted chimeric antigen receptor (CAR) T cell therapy approved for the treatment of adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Some patients (pt…
View article: Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study
Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study Open
Introduction: The combination of a DNA methyltransferase inhibitor (DNMTi) and the BCL2 inhibitor venetoclax (VEN) is effective for newly-diagnosed acute myeloid leukemia (AML). However, response rates of VEN/DNMTi are lower for other adva…
View article: Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics Open
Background: Dismal survival outcomes are characteristic of pts with AML harboring very-high risk cytogenetics (vHRC), which can be attributed to aggressive disease biology and low and poorly durable response rates to conventional cytotoxic…
View article: Rapid Epigenomic Classification of Acute Leukemia
Rapid Epigenomic Classification of Acute Leukemia Open
Introduction Accurate molecular subtyping of acute leukemia (AL) is imperative for optimal risk stratification and treatment selection. Currently, diagnostic categories in AL are based on morphologic, immunophenotypic, and genetic features…
View article: Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia Open
Background: We hypothesized that the addition of the BCL-2 inhibitor venetoclax (VEN) in combination with daunorubicin/cytarabine (3+7) induction (ind) and high dose cytarabine (ara-C) consolidation (consol) in previously untreated adults …
View article: Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort
Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort Open
Acquired hemophilia A (AHA) is an autoimmune bleeding disorder that is caused by factor VIII (FVIII) autoantibodies with high morbidity and mortality due to bleeding and complications from immunosuppression (IST). To address the real-world…
View article: Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL Open
The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189 patient…
View article: Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in <i>NPM1</i>-mutant AML
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in <i>NPM1</i>-mutant AML Open
Although intensive induction chemotherapy (IC) remains the standard of care for younger patients with acute myeloid leukemia (AML), hypomethylating agents + venetoclax (HMA/VEN) can lead to durable remission among older patients with nucle…
View article: Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era Open
Progression of myeloproliferative neoplasms (MPNs) to accelerated or blast phase is associated with poor survival outcomes. Since 2017 there have been several therapies approved for use in acute myeloid leukemia (AML); these therapies have…
View article: Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients Open
The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML patients, we evaluated whether molecular ontogeny subgroups have …
View article: Tri‐ing to decipher trisomy<scp>AML</scp>
Tri‐ing to decipher trisomy<span>AML</span> Open
Lam et al. compared trisomy acute myeloid leukaemia (AML) patients (inclusive of single trisomy, double trisomy or tetrasomy cases) with cytogenetically normal AML to uncover distinguishing molecular and prognostic features of trisomy AML.…
View article: Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in <i>IDH1-</i> or <i>IDH2</i>-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study
Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in <i>IDH1-</i> or <i>IDH2</i>-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study Open
Introduction: Intensive induction chemotherapy (IC) remains the standard of care for younger and fit patients (pts) with acute myeloid leukemia (AML). Post-hoc analyses from clinical trials have associated IDH1 and IDH2 mutations with high…
View article: Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid Leukemia
Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid Leukemia Open
Introduction: Detection of measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplant (alloHCT) in patients with acute myeloid leukemia (AML) in remission is associated with increased relapse and inferior survival …
View article: Measurable Residual<i>IDH1</i>before Allogeneic Transplant for Acute Myeloid Leukemia
Measurable Residual<i>IDH1</i>before Allogeneic Transplant for Acute Myeloid Leukemia Open
Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. The persistence of mutated NPM1 or FLT3 -ITD in the blo…
View article: <i>FLT3-ITD</i> does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
<i>FLT3-ITD</i> does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years Open
[Figure: see text]
View article: Table S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Table S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Patient disposition.
View article: Data from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Data from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Purpose:Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) have poor outcomes and require new therapies. In AML, autocrine production of hepatocyte growth factor (HGF) drives MET signaling that promotes myeloblast growth …
View article: Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Survival outcomes for the overall cohort. A, Progression-free survival. B, Overall survival.
View article: Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Study design.